Sat, 01 Oct 2022

NEW YORK, NY / ACCESSWIRE / August 12, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Unilever PLC (NYSE: UL)

CONTACT JAKUBOWITZ ABOUT UL:
https://claimyourloss.com/securities/unilever-plc-loss-submission-form/?id=30806&from=1

This lawsuit is on behalf of all persons who purchased or otherwise acquired Unilever American Depositary Receipts between September 2, 2020 and July 21, 2021, inclusive.

Lead Plaintiff Deadline : August 15, 2022

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: a) in July 2020, the board of Ben & Jerry's, one of Unilever's marquee brands, passed a resolution to end sales of its ice cream in 'Occupied Palestinian Territory' ; and b) this boycott decision risked adverse governmental actions for violations of laws, executive orders, or resolutions aimed at discouraging boycotts, divestment, and sanctions of Israel adopted by 35 U.S. states.

Inotiv, Inc. (NASDAQ:NOTV)

CONTACT JAKUBOWITZ ABOUT NOTV:
https://claimyourloss.com/securities/inotiv-inc-loss-submission-form/?id=30806&from=1

Class Period: September 21, 2021 - June 13, 2022

Lead Plaintiff Deadline: August 22, 2022

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Inotiv's acquisition, Envigo RMS, LL ('Envigo'), and Inotiv's Cumberland, Virginia facility (the 'Cumberland Facility') engaged in widespread and flagrant violations of the Animal Welfare Act ('AWA'); (2) Envigo and Inotiv's Cumberland Facility continuously violated the AWA; (3) Envigo and Inotiv did not properly remedy issues with regards to animal welfare at the Cumberland Facility; (4) as a result, Inotiv was likely to face increased scrutiny and governmental action; (5) Inotiv would imminently shut down two facilities, including the Cumberland Facility; (6) Inotiv did not engage in proper due diligence; and (7) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Molecular Partners AG (NASDAQ:MOLN)

CONTACT JAKUBOWITZ ABOUT MOLN:
https://claimyourloss.com/securities/molecular-partners-ag-loss-submission-form/?id=30806&from=1

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Molecular Partners American Depositary Shares pursuant and/or traceable to certain documents issued in connection with the Company's initial public offering conducted on or about June 16, 2021; and/or (b) Molecular Partners securities between June 16, 2021, and April 26, 2022.

Lead Plaintiff Deadline: September 12, 2022

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's product, ensovibep, was less effective at treating COVID-19 than defendants had led investors to believe; that (ii) accordingly, the the U.S. Food and Drug Administration ('FDA') was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug Emergency Use Authorization ('EUA'); (iii) waning global rates of COVID-19 significantly reduced the Company's chances of securing EUA for ensovibep; (iv) another of the Company's product candidates, MP0310, was less attractive to Molecular Partners' collaborator, Amgen, than defendants had led investors to believe; (v) accordingly, there was a significant likelihood that Amgen would return to global rights of MP0310 to Molecular Partners; (vi) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (vii) as a result, documents issues in connection with the Company's initial public offer and defendants' public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

Jakubowitz Law, Friday, August 12, 2022, Press release picture

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law



View source version on accesswire.com:
https://www.accesswire.com/711903/LAWSUITS-FILED-AGAINST-UL-NOTV-and-MOLN--Jakubowitz-Law-Pursues-Shareholders-Claims

More Houston News

Access More

Sign up for Houston News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!